MD Anderson-led Phase III trial finds targeted therapy lowers risk of death, is well-tolerated ABSTRACT LBA1008 HOUSTON ― Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. The combination resulted in 70.2 percent OS at 42 month follow up compared […]
